Serina Therapeutics, Inc. cotiza a 1.94 USD y tiene una capitalización bursátil de $49M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the P…
| Periodo | 2026-05 | 2026-03 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | $-0.53 | $-0.31 | $-0.51 | $-0.66 |
| Estimado | $-0.44 | $-0.50 | $-0.53 | $-0.42 |
| Sorpresa | -20.5% | +38.0% | +3.8% | -57.1% |
| Métrica | SER | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -18478.5% | -38.6% | -18439.8% |
| Net Margin | -14755.4% | -33.6% | -14721.8% |
| FCF Margin | -13856.9% | -13.9% | -13843.1% |
| ROE | — | -40.4% | — |
| ROA | -276.0% | -32.0% | -243.9% |
| Current Ratio | 1.71 | 2.84 | -1.13 |
| Debt / Equity | — | 0.28 | — |